




FIG. 1

BASELINE DEMOGRAPHICS (FAS)

Characteristics	Statistics	Tricaprylin (N=40)	Placebo (N=41)	Total (N=81)
Age	n	40	41	81
	Mean	44.8	46.9	45.8
	SD	12.21	11.50	11.83
	Median	46.0	49.0	48.0
	Min, Max	18, 70	22, 66	18, 70
Sex				
Female	n (%)	30 (75.0%)	35 (85.4%)	65 (80.2%)
Male	n (%)	10 (25.0%)	6 (14.6%)	16 (19.8%)
Race				
White	n (%)	38 (95.0%)	37 (90.2%)	73 (90.1%)
Indian/ Indian sub-continent	n (%)	0 (0.0%)	1 (2.4%)	1 (1.2%)
Chinese	n (%)	1 (2.5%)	0 (0.0%)	1 (1.2%)
Japanese	n (%)	1 (2.5%)	0 (0.0%)	1 (1.2%)
Aboriginal Australian	n (%)	0 (0.0%)	3 (7.3%)	3 (3.7%)
Other	n (%)	0 (0.0%)	1 (2.4%)	1 (1.2%)

Mostly balanced between treatment arms; tricaprylin arm had higher proportion of men

FIG. 2

BASELINE DEMOGRAPHICS (FAS)

Characteristics		Tricaprylin (N=40)		Placebo (N=41)		Total (N=81)
Height (cm)	n	40	41			81
	Mean	170.30	167.21			168.73
	SD	7.844	10.653			9.442
	Median	170.00	167.00			168.00
	Min, Max	156.0, 189.0	151.5, 195.0			151.5, 195.0
Weight (kg)	n	40	41			81
	Mean	80.086	74.939			77.481
	SD	23.8935	15.9503			20.3033
	Median	77.950	73.900			75.000
	Min, Max	50.50, 171.00	41.80, 113.00			41.80, 171.00
BMI (kg/m ²)	n	40	41			81
	Mean	27.37	26.80			27.08
	SD	6.860	5.343			6.107
	Median	26.10	27.40			26.60
	Min, Max	18.7, 51.1	17.9, 40.3			17.9, 51.1

Tricaprylin arm had a higher mean weight, though BMI was similar

FIG. 3

BASELINE NUMBER OF MIGRAINE HEADACHE DAYS


Characteristics		Statistics		Tricaprylin (N=31)	Placebo (N=31)	Total (N=62)
Number of MHDs during Baseline Period		n		31	31	62
		Mean		12.4	10.3	11.3
		SD		6.37	5.91	6.19
		Median		10.8	8.0	9.2
		Min, Max		2.1, 24	2.2, 28	2.1, 28
Chronic vs. Episodic during Baseline Period						
Episodic (<=14 MHDs/Month)		n (%)		19 (61.3%)	27 (87.1%)	46 (74.2%)
Chronic (> 14 MHDs/Month)		n (%)		12 (38.7%)	4 (12.9%)	16 (25.8%)

Higher proportion of subjects in the tricapyrylin arm with chronic migraine

FIG. 4

PRIMARY EFFICACY ANALYSIS – INTENDED TITRATION EVALUABLE FOR EFFICACY SET (EETS)

Figure 18.2.1.12
Least Squares Change from Baseline in Migraine Residuals Days Over Time
Evaluable for Efficacy Intention to Treat



Efficacy at Month 2, positive trend at Month 3

FIG. 5

PRIMARY EFFICACY ANALYSIS – EEITS subgroup with 4-24 MHDs at baseline





FIG. 6

STATISTICAL ANALYSIS OF THE PRIMARY ENDPOINT

Month	Pop ^a	Treatment	N	Least Squares Mean	Diff in Least Squares Means	95% CI	1-sided p-value	95% CI	2-sided p-value
Month 1	EES	Tricaprolin	31	-1.01	1.03	{-0.31, 2.37}	0.835	{-1.04, 3.10}	0.323
		Placebo	31	-2.04					
	EETS	Tricaprolin	15	-0.53	1.24	{-1.72, 3.71}	0.744	{-2.64, 5.13}	0.512
		Placebo	9	-1.77					
Month 2	EES	Tricaprolin	22	-4.98	-3.75	{-4.57, -0.93}	0.028	{-5.57, -0.07}	0.056
		Placebo	23	-3.23					
	EETS	Tricaprolin	10	-4.46	-3.27	{-6.04, -0.51}	0.065	{-7.62, 1.06}	0.132
		Placebo	8	-1.18					
Month 3	EES	Tricaprolin	21	-3.4	0.92	{-1.26, 3.09}	0.707	{-2.46, 4.30}	0.585
		Placebo	19	-4.3					
	EETS	Tricaprolin	10	-4.7	-1.49	{-4.69, 1.70}	0.269	{-6.60, 3.62}	0.539
		Placebo	7	-3.2					

Results of MMRM analyses in EES and EETS
FIG. 7

PRIMARY ENDPOINT IN EPISODIC AND CHRONIC SUBJECTS (EES 4-24 MHDs)



N	Month 1	Month 2	Month 3
Tricaptin	17	12	12
Placebo	22	15	12

FIG. 8A

Different trajectory for episodic and chronic subjects

N	Month 1	Month 2	Month 3
Tricaptin	12	8	7
Placebo	6	5	5

FIG. 8B

SECONDARY ENDPOINT – CHANGE FROM BASELINE IN ACUTE MIGRAINE MEDICATION USE (EES)




FIG. 9

SECONDARY ENDPOINT – CHANGE FROM BASELINE IN ACUTE MIGRAINE MEDICATION USE (EETIS)




FIG. 10

SECONDARY ENDPOINTS: RESPONDER ANALYSIS, MHD50, MHD75, MHD90 (EES)

Endpoint	Time	Statistic	Ticagrelor N = 31	Placebo N = 31	One-sided p-value
MHD50	Month 1	n (%)	3 (9.7%)	7 (22.6%)	0.360
	Month 2	n (%)	13 (41.9%)	8 (25.8%)	0.142
	Month 3	n (%)	8 (25.8%)	7 (22.6%)	0.500
MHD75	Month 1	n (%)	1 (3.2%)	1 (3.2%)	0.764
	Month 2	n (%)	4 (12.9%)	3 (9.7%)	0.500
	Month 3	n (%)	4 (12.9%)	5 (16.1%)	0.764
MHD90	Month 1	n (%)	1 (3.2%)	0	0.500
	Month 2	n (%)	3 (9.7%)	2 (6.5%)	0.500
	Month 3	n (%)	1 (3.2%)	3 (9.7%)	0.344

FIG. 11

SECONDARY ENDPOINTS: RESPONDER ANALYSIS, MHD50, MHD75, MHD90 (EITS)

Endpoint	Time	Statistic	Ticagrelor N = 15	Placebo N = 9	One-sided p-value
MHD50	Month 1	n (%)	3 (20.0%)	1 (11.1%)	0.514
	Month 2	n (%)	7 (46.7%)	2 (22.2%)	0.225
	Month 3	n (%)	5 (33.3%)	3 (33.3%)	0.675
MHD75	Month 1	n (%)	1 (6.7%)	0	0.625
	Month 2	n (%)	3 (20.0%)	1 (11.1%)	0.514
	Month 3	n (%)	3 (20.0%)	2 (22.2%)	0.745
MHD90	Month 1	n (%)	1 (6.7%)	0	0.625
	Month 2	n (%)	2 (13.3%)	1 (11.1%)	0.692
	Month 3	n (%)	1 (6.7%)	1 (11.1%)	0.670

FIG. 12